P L A I N L A N G U A G E S U M M A R Y
No strong evidence to be certain of the safety of any particular type of colloid solution for replacing blood fluids When a person is bleeding heavily, the loss of fluid volume in their veins can lead to shock, so they need fluid resuscitation. Colloids and crystalloids are two types of solutions used to replace lost blood fluid (plasma). They include blood and synthetic products. Both types appear to be similarly effective at resuscitation, but one type of colloid (human albumin) was found by another Cochrane review to increase deaths. Different colloids may have different effects. However, the review of trials found there is not enough evidence to be sure that any particular colloid is safer than any other
B A C K G R O U N D
Colloids are used as plasma substitutes for short-term replacement of fluid volume, while the cause of the problem is being addressed (e.g. stopping bleeding). These solutions can be blood products (human albumin solution, plasma protein fraction [PPF] ) or synthetic (modified gelatins, dextrans, etherified starches). Colloid solutions are widely used in fluid resuscitation (Yim 1995) and they have been recommended in a number of resuscitation guidelines and intensive care management algorithms (Armstrong 1994; Vermeulen 1995) . Previous systematic reviews have suggested that colloids are no more effective than crystalloids in reducing mortality (Schierhout 2000) , and that albumin administration may increase mortality compared to crystalloids or no fluid in a range of uses (CIGAR 2000) . Despite this, colloid solutions are still widely used as they are thought to remain in the intravascular space for longer than crystalloids and, therefore, be more effective in maintaining osmotic pressure.
It is plausible that colloids may vary in their safety and effectiveness. Different colloids vary in the length of time they remain in the circulatory system. It may be that some low to medium molecular weight colloids (e.g. gelatins and albumin) are more likely to leak into the interstitial space (Traylor 1996) , whereas some larger molecular weight hydroxyethyl starches are retained for longer (Boldt 1996) . In addition it is thought that some colloids may effect coagulation or cause other adverse effects.
The previous review of colloids against crystalloids only allows indirect comparison of the different colloids. This review examines direct comparisons of the different colloid solutions in randomised trials to complement the earlier reviews on colloids compared to crystalloids (Schierhout 2000) and human albumin (CIGAR 2000) .
O B J E C T I V E S
To quantify the relative effects on mortality of different colloid solutions in critically ill and surgical patients requiring volume replacement, by examining direct comparisons of colloid solutions.
C R I T E R I A F O R C O N S I D E R I N G S T U D I E S F O R T H I S R E V I E W

Types of studies
Randomised and quasi-randomised (e.g. allocation by hospital number or alternation) controlled trials.
Types of participants
Patients clinically assessed as requiring volume replacement or maintenance of colloid osmotic pressure. Administration of fluid for preoperative haemodilution or volume loading, during plasma exchange, for priming extracorporeal circuits or following paracentesis are excluded.
Types of intervention
The colloid solutions considered are human albumin solutions, plasma protein fraction, modified gelatins, dextran 70, or etherified starch solutions.
Trials of other blood products not used primarily for volume replacement (e.g. fresh frozen plasma, pooled serum) were excluded.
The review compares the administration of any regimens of different classes of colloids with each other.
Types of outcome measures
The primary outcome measure is mortality from any cause at the end of the study period. We also attempted to find data on incidence of adverse reactions, allergies or anaphylactic shock, and the amount of blood (whole blood or red blood cells) transfused in each group. Some of the synthetic colloids may have anticoagulant properties and, therefore, we felt that some measure of blood loss or haemorrhage was important. However, as blood loss is too vulnerable to measurement error, we decided to use the amount of blood products transfused as an outcome measure.
Intermediate physiological outcomes were not used for several reasons. These were that they are subject to intra-and inter-observer variation, they have no face value to patients and relatives, and the ones seen as appropriate are not stable over time. Also there would need to exist a strong predictive relationship between the variable and mortality.
S E A R C H M E T H O D S F O R I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Injuries Group methods used in reviews.
We searched the Cochrane Injuries Group trials register, the Cochrane Controlled Trials Register (2002 Issue 3), MEDLINE (1966 -2002 /07), and EMBASE (1974 -2002 August week 1). Bibliographies of trials retrieved were searched, and drug companies manufacturing colloids were contacted for information. The search was last updated in September 2002. Search strategies for each database are given below.
Cochrane Injuries Group Trials Register: #1 albumin* or hypoalbumin* or plasma* or volume* or starch* or dextran* or gelofus* or haemacc* or hemacc* or colloid*.
Cochrane Controlled Trials Register (CD, 2002 issue 3): #1 explode "Albumins" / all SUBHEADINGS #2 explode "Plasma" / all SUBHEADINGS #3 explode "Plasma-Substitutes" / all SUBHEADINGS #4 (volume next replac*) or (human next albumin*) #5 (frozen next plasma) or (fresh next plasma) #6 plasma next protein* #7 (low next albumin*) or hypoalbumin* #8 starch or dextran* or gelofus* or haemacc* or hemacc* #9 colloid or colloids #10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9.
MEDLINE (Silverplatter, 1966 (Silverplatter, -2002 ): #1 explode "Albumins" / all SUBHEADINGS #2 explode "Plasma" / all SUBHEADINGS #3 explode "Plasma-Substitutes" / all SUBHEADINGS #4 (volume next replac*) or (human next albumin*) #5 (frozen next plasma) or (fresh next plasma) #6 plasma next protein* #7 (low next albumin*) or hypoalbumin* #8 starch or dextran* or gelofus* or haemacc* or hemacc* #9 colloid or colloids #10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 #11 #10 and (optimally sensitive MEDLINE search strategy for identifying randomised controlled trials) (Clarke 2001).
EMBASE (Ovid, 1974 (Ovid, -2002 There were no language restrictions in any of the searches.
M E T H O D S O F T H E R E V I E W
Trial identification
One reviewer examined the electronic search results for reports of possibly relevant trials and these reports were then retrieved in full. Two reviewers (PA and FB) applied the selection criteria independently to the trial reports, resolving disagreements by discussion.
Quality assessment
Since there is evidence that the quality of allocation concealment particularly affects the results of studies (Schulz 1995), two reviewers scored this quality on the scale used by Schulz (Schulz 1995) as shown below, assigning C to poorest quality and A to best quality: A=trials deemed to have taken adequate measures to conceal allocation (i.e. central randomisation; numbered or coded bottles or containers; drugs prepared by the pharmacy; serially numbered, opaque, sealed envelopes; or other description that contained elements convincing of concealment).
B=trials in which the authors either did not report an allocation concealment approach at all or reported an approach that did not fall into one of the other categories.
C=trials in which concealment was inadequate (such as alternation or reference to case record numbers or to dates of birth)
Where the method used to conceal allocation was not clearly reported, the author was contacted, if possible, for clarification. We then compared the scores allocated and resolved differences by discussion.
Data extraction
Two reviewers independently extracted information on the following: method of allocation concealment, number of randomised patients, type of participants and the interventions. The outcome data sought were numbers of deaths, volume of blood transfused, and incidence of adverse or allergic reactions. The reviewers were not blinded to the authors or journal when doing this, as the value of this has not been established (Berlin 1997) . Results were compared and any differences resolved by discussion.
Where there was insufficient information in the published report, we attempted to contact the authors for clarification.
Analysis
The following comparisons were made: -albumin or PPF vs etherified starch -albumin or PPF vs modified gelatin -albumin or PPF vs dextran 70 -modified gelatin vs etherified starch -modified gelatin vs dextran 70 -etherified starch vs dextran 70.
For each trial the relative risk of death and 95% confidence interval was calculated, such that a relative risk of more than 1 indicates a higher risk of death in the first group named. Relative risk was chosen as a measure, as it is more readily applied to the clinical situation.
The groups of trials were examined for statistical evidence of heterogeneity using a chi-square test. If there was no obvious heterogeneity on visual inspection or statistical testing, pooled relative risks and 95% confidence intervals were calculated using a fixed-effects model.
We assessed the skewness of continuous data by checking the mean and standard deviation (if available). If the standard deviation is more than twice the mean for data with a finite end point (such as 0 in the case of bleeding), the data are likely to be skewed and it is inappropriate to apply parametric tests (Altman 1996) . This is because the mean is unlikely to be a good measure of central tendency. If parametric tests could not be applied, we tabulated the data.
The effect of excluding trials judged to have inadequate (scoring C) allocation concealment were examined in a sensitivity analysis.
D E S C R I P T I O N O F S T U D I E S
For more detailed descriptions of individual studies, please see the table of included studies.
A total of 57 trials met the inclusion criteria, with a total of 3659 participants. The earliest trial was from 1980 and the most recent from 2001. From the drug companies we contacted, we were sent information by Hoechst, Baxter Health Care Ltd, Fresenius Ltd, CIS UK Ltd, and Rhemoacrodex. No new trials were identified from the information sent to us. the trials. Information on the amount of blood transfused was available in 31 of the trials. However this was reported in a variety of different ways that made combining the data in a meta-analysis unfeasible.
Inclusion and exclusion criteria varied, but many of the studies excluded patients with previous adverse reactions to colloids, clotting problems, or renal disease.
M E T H O D O L O G I C A L Q U A L I T Y
Using predefined criteria (Schulz 1995) the quality of allocation concealment was judged to be adequate in 20 trials, unclear in 29 trials and inadequate in eight trials. Where the method of allocation concealment was unclear, we attempted to contact all of the trialists and we obtained information from 11 of them. However, due to the lack of reported information on the process of randomisation and allocation concealment, we were unable to properly assess the quality of the majority of the trials. Ten trials mentioned blinding. In four of these those giving the treatment were blinded, in four those giving post-operative care and were blinded and in the other two trials the outcome assessors were blinded.
R E S U L T S
Of the 57 trials identified 24 reported mortality data. Information on death was obtained from a further 12 trials by contact with the authors. We therefore had data on death from 36 trials.
Albumin or PPF vs starch: Twenty trials (1029 participants) reported mortality data. The pooled relative risk was 1.17 (95% CI 0.91-1.50).
Albumin or PPF vs gelatin: Four trials (542 participants) reported mortality but only one of those trials had any deaths. The relative risk was 0.99 (95% CI 0.69-1.42).
Albumin or PPF vs dextran: Three trials reported mortality and were included in the metaanalysis. There were no deaths so relative risk was not estimable.
Gelatin vs starch:
Eleven trials (945 participants) reported mortality and the pooled relative risk was 1.00 (95% CI 0.78-1.28).
Gelatin vs dextran 70 There were two trials which reported mortality. There were no deaths so the relative risk was not estimable.
Hydroxyethyl starch vs dextran 70: No trials reported mortality.
Thirty-five trials recorded the amount of blood transfused. As the data was reported in various ways, often lacking a measure of variation, and was also skewed we did not attempt a quantitative synthesis. This data can be seen in the "other data" table. Fifteen trials reported the incidence of adverse or allergic reactions or anaphylactic shock: all reported that there were no such incidents.
The effect of excluding trials judged to have inadequate (scoring C) allocation concealment was examined in a sub-group analysis. This made no significant difference to the results.
D I S C U S S I O N
Despite finding 57 trials we cannot make any conclusions about the relative effectiveness of different colloid solutions. A previous review suggested that albumin may increase mortality in critically ill patients (CIGAR 2000) , but there are too few data available to show in direct comparisons whether the synthetic alternatives are safer. The confidence intervals are wide and do not exclude clinically significant differences between colloids.
Mortality was selected as the main outcome measure in this systematic review for several reasons. In the context of critical illness, death or survival is a clinically relevant outcome that is of immediate importance to patients, and data on death are reported in many of the studies. Furthermore, one might expect that mortality data would be less prone to measurement error or biased reporting than would data on pathophysiological outcomes. The use of a pathophysiological end point as a surrogate for an adverse outcome assumes a direct relationship between the two, an assumption that may sometimes be inappropriate. Finally, when trials collect data on a number of physiological end-points, there is the potential for bias due to the selective publication of endpoints showing striking treatment effects.
There was wide variation in the participants, intervention regimens, and the length of follow-up. The length of follow-up is not reported in many of the studies. Where it is reported it ranges from a matter of hours to months, which may explain a lot of the heterogeneity in overall event rates. The effect of these factors was not examined in a sensitivity analysis, as there was felt to be insufficient data to justify examining subgroups.
Many of the trials were small, and some had been done some time ago. Although older trials will not necessarily be of poorer quality, it may be that treatment protocols have subsequently altered making these trials less relevant to current clinical practice.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Previous reviews have failed to show any benefit of colloids over crystalloids for volume replacement (Schierhout 2000) and suggested that albumin solution may increase mortality in critically ill patients (CIGAR 2000) . This review does not provide any evidence that one colloid is safer than another, but does not rule out clinically significant differences.
Implications for research
Trials of fluid therapy need to be larger in order to exclude clinically significant differences between colloids in patient relevant outcomes. However, trials should probably first address the question of whether colloids are any more effective than crystalloid solutions.
Use of surrogate outcomes, such as physiological measurements should be discouraged unless there is a strong relationship with outcomes of interest to patients and relatives. 
P O T E N T I A L C O N F L I C T O F I N T E R E S T
None known.
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• University of Hertfordshire UK Follow-up was for one hour. Two patients in the HES grp were excluded because they experienced haemodynamic instability. The final analysis was made on remaining 16 patients.
R E F E R E N C E S
References to studies included in this review
Allocation concealment A -Adequate
Study Beards 1994
Methods Randomised controlled trial (allocation by alternation). Information on allocation concealment was obtained on contact with the author. Participants 28 patients with hypovolaemia, mechanically ventilated for concurrent acute respiratory failure. Patients fulfilled the following inclusion criteria: age >16 yrs, body weight between 50 and 85kg, mean arterial pressure <80mmHg (or 30mmHg less than previously recorded); pulmonary artery occlusion pressure <10mmHg with oliguria (i.e urine output <15 ml/hr).
Interventions 1) Rapid infusion of 500ml modified fluid gelatin (n=15). 2) Rapid infusion of 500ml hetastarch (n=13).
Outcomes Haemodynamic variables were measured for 30 minutes. Oxygen variables were measured for 30 minutes. Deaths in hospital reported.
Notes
Patients were followed up to discharge from hospital.
Allocation concealment C -Inadequate
Study Berard 1995
Methods Randomised controlled trial. A set of 200 tickets (type 1) and another set of 200 tickets (type 2) were mixed in a box. One ticket was drawn at random for each patient. Information on method of randomisation was obtained on contact with the author. Blinding not mentioned.
Participants 319 patients in a resuscitation service receiving medical (gastrointestinal haemorrhage) and surgical cases. Patients were excluded if they had had a prior allergic reaction.
Interventions 1) Gelatin (n=153). 2) HES (n=146)
The prescribers chose the quantity of colloid, guided by normal practice.
Outcomes Death. Amount of colloid and red blood cells given.
Cost. Notes 20 patients lost to follow up, no explanation given. Follow up to discharge.
Allocation concealment C -Inadequate
Study Beyer 1997
Methods Randomised controlled trial. Allocation was by a list of random numbers read by someone not entering patients into the trial (closed list). Information on method of allocation concealment was obtained by contact with the author. No blinding.
Participants 48 patients undergoing major elective hip surgery with an expected blood loss of >1000 ml. Exclusion criteria were haemoglobin concentration < or equal to 11g/dl, heart failure and coronary artery disease, myocardial infarction within the past 6 months, hypertension (>180mmHg systolic), impaired renal function, pregnancy, known hypersensitivity to HES or gelatin, patient taking drugs that may specifically affect blood viscosity, diuresis or clotting. Deaths were reported for the study period (when there were no deaths) and after the study period (when there was 1 death in the HES 70 grp, 2 deaths in the HES 200 grp and 1 death in the gelatin grp). The study period lasted until the first day post-op.
Allocation concealment A -Adequate
Study Boldt 2001
Methods Randomised controlled trial. Allocation by a "closed envelope system". Volume therapy was done by doctors who did not know the aim of the study.
Participants 75 patients undergoing major abdominal surgery. Volume was administered to keep the CVP between 8 and 12mmHg.
Interventions 1) 6% HES (n=25). 2) 6% HES (n=25).
3) 4% modified fluid gelatin (n=25) All groups also received 500ml of ringers lactate for each hour of surgery.
Outcomes Death. Haemodynamic variables, blood loss, blood transfused. Notes There were no deaths in the study period (until first postoperative day) but afterwards there was one death in the colloids group and no deaths in the gelatin group.
Allocation concealment A -Adequate
Study Brock 1995
Methods Randomised controlled trial with list of random numbers read by someone entering patients into the trial (open list). Data on allocation concealment was obtained on contact with the authors. Participants 21 patients who had undergone cardiac surgery.
Interventions 1) 10% HES. 200/0.5 in 7.2% saline (n=7) 2) 5% human albumin (n=7).
3) 6% hydroxyethylstarch in 0.9% saline (n=7).
Outcomes
Hemodynamic variables were collected. Data on death was obtained on contact with the authors. Notes
Allocation concealment C -Inadequate
Study
Brutocao 1996
Methods Randomised double-blind controlled trial with pharmacy controlled randomisation. Information on allocation concealment was obtained on contact with the authors. Participants
Children aged 1 year or more who were undergoing surgical repair of a congenital heart disease. Exclusion criteria included amrinone therapy, renal disease, coagulopathy or a known bleeding diathesis.
Interventions 1) 5% albumin (n=18).
2) 6% HES (n=20). Volume expansion was administered as clinically indicated to maintain adequate central venous pressure, perfusion and urine output. The total amount of colloid therapy was determined by care providers blinded to the randomisation. Outcomes Haemodynamic variables. Coagulation variables. Information on death was obtained on contact with the authors. Notes Follow-up was until discharge from hospital. 9 children excluded post randomisation because they did not require colloid.
Allocation concealment A -Adequate
Study Carli 2000
Methods Randomised controlled trial. Each centre had a list and the patients were randomised by the regulatory Dr of the Institute. Participants 164 trauma patients. Patients were included if their SBP was less than 100mmHg, associated with signs of hypoperfusion.
Interventions 1) HES (Hesteril 6%) (n= 85).
2) Gelatin (Plasmion)
Outcomes Glasgow coma score. Haemodynamic variables Units of blood transfused Adverse reaction Notes There were 13 deaths from heart failure but these patients were excluded from the final analysis.
Allocation concealment B -Unclear
Study Claes 1992
Methods Randomised controlled trial. No information given on method of randomisation.
Blinding not mentioned. No loss to follow up.
Participants 20 patients undergoing brain tumor surgery and 20 patients undergoing transabdominal hysterectomy. Exclusion criteria were preexisting coagulopathies; abnormal preoperative coagulation screening tests; intake of drugs affecting haemostasis within 2 wk preoperatively as well as liver or kidney dysfunction.
Interventions 1000ml of fluid for volume replacement, either as 1) 6% HES (n=19).
2) 5% human albumin solution in 0.9% NaCl (n=21). Participants 30 patients post cardiac surgery. Patients were included if they were haemodynamically stable, were without serious 'rhythm' problems, had a mean arterial pressure less than 90mmHg, a mean pulmonary artery pressure less than 20mmHg and a central venous pressure less than 10mmHg. Patients excluded if they needed blood transfusion, had a hematocrit less than 28% or haemoglobin less than 9g/100ml.
Outcomes
Interventions 1) 4% human albumin (n=15).
2) Haemaccel (n=15).
Haemodynamic parameters.
Notes
Follow up 4 hours.
Allocation concealment B -Unclear
Study Dytkowska 1998
Methods Randomised controlled trial. No information given on method of allocation concealment Participants 40 patients post cardiac surgery. Patients were excluded if they had co-existing cardiogenic shock, renal failure with creatine level over 3.0mg or severe clotting disorders.
Interventions 1) 200/0 HAES 6% (n=20).
2) Gelafundin (n=20) Colloids were administered to patients with diagnosed symptoms of hypovolaemia, during the first 24 hours post-op. Infusion rate was adjusted to patients needs but it did not exceed 1000ml/h Interventions 1) 1g/kg of albumin 5% solution (n=20).
2) 1g/kg or hetastarch 6% solution (n=20).
Outcomes
Haemodynamic and coagulation variables were measured. Data on death was obtained on contact with the author.
Notes
Length of follow up not specified.
Allocation concealment C -Inadequate
Study Haisch 2001a
Methods Randomised controlled trial. No information given on method of allocation concealment. Patient management by doctors who were blided to the grouping.
Participants 42 patients undergoing cardiac surgery. Patients were excluded if they had: an MI within previous 3 months, renal insufficiency, liver insufficiency, non controlled diabetes mellitus, preoperative coagulation abnormalities or patients treated with heparin or cyclooxygenase inhibitors within last 7 days.
Interventions 1) Gelatin (n=21).
2) HES (n=21).
Outcomes
Deaths.
Use of blood products.
Notes
Follow up until first postoperative day.
Allocation concealment B -Unclear
Study
Haisch 2001b
Methods Randomised controlled trial using computer generated random numbers. No information given on allocation concealment. Participants 42 patients undergoing major abdominal surgery for malignancies.
Patients were excluded if they had cardiac insufficiency, renal insufficiency, altered liver function, pre-operative anemia, pre-operative coagulation abnormalities or if they had had cycloxygenase inhibitors.
Interventions 1) HES (n=21).
2) Gelatin (n=21) until the morning of the first post-operative day.
Outcomes Death. Use of allogenic blood products.
Coagulation variables.
Notes
Allocation concealment B -Unclear
Study Hausdorfer 1986
Participants 30 children undergoing major surgery. During about 3 hours of surgery, the patients lost up to 15% of blood volume.
Interventions 1) Human albumin 5% (n=15).
2) HES 6% (n=15) with 14ml/kg body weight each, respectively. 
Allocation concealment B -Unclear
Study
Rackow 1983
Methods Randomised controlled trial, method of allocation concealment not mentioned. Blinding not mentioned.
Participants 18 patients with hypovolemic and septic shock. Patients were excluded if they were less than 18 yrs of age, considered to be in a terminal state, or had a significant coagulopathy.
Interventions 1) albumin (n=9). 2) HES (n=9).
Patients received 250ml of the treatment fluid every 15 min as a fluid challenge. The fluid challenge ended when the WP equalled 15 mmHg. Thereafter the treatment fluid was given in sufficient quantities to maintain the WP at 15mmHg for the next 24h, at which point the study was completed.
Outcomes Death. Haemodynamic variables. Respiratory variables.
Notes
Deaths given for study period and for length of hospital stay. Survival until discharge was used for the mortality data for this review.
Allocation concealment B -Unclear
Study
Rackow 1989
Methods Randomised controlled trial. Method of allocation concealment was not recorded.
No loss to follow up.
Blinding not mentioned.
Participants 20 patients with severe sepsis and systemic hypoperfusion. Patients were excluded from the study if they were <21 yrs of age, pregnant, considered to be terminal, or they manifested spontaneous bleeding. 
